Abstract: The present study was aimed to find possible role of pioglitazone (PPARγ agonist) and fenofibrate (PPARα agonist) by Triton induced hyperlipidemia Model, Diet induced model and Relative organ weight analysis.. The study revels that, both pioglitazone and fenofibrate has significantly reduced the elevated levels of serum triglycerides and cholesterol in both atherogenic diet and triton induced hyperlipidemia at 3 mg kg-1 b.wt. Significant increase in HDL level was observed in animals treated with pioglitazone 3 mg kg-1 b.wt. and fenofibrate 3 mg kg-1 b.wt. in animals induced hyperlipidemia with atherogenic diet. The liver enzymes reveal that, there was significant reverse in ASAT levels in animals treated with pioglitazone 3 mg kg-1 b.wt. and fenofibrate 3 mg kg-1 b.wt. Histopathology reports also suggest that, there was a protection to liver and heart against atherogenic and triton induced damage. In combination therapy of both pioglitazone and fenofibrate in atherogenic diet and triton induced hyperlipidemia,there was no potentiation in their activity when they have administered in combination.